
|Videos|December 16, 2022
Cabazitaxel for the Treatment of mCRPC: Data From the PROSELICA and FIRSTANA Trials
Author(s)Neal Shore, MD, FACS
Neal Shore, MD, FACS, discusses data from the PROSELICA and FIRSTANA trials investigating cabazitaxel for the treatment of mCRPC, including a look at the post-hoc analyses of PROSELICA.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5












